A commitment from longtime supporters Patricia and James Poitras ’63 initiates multidisciplinary efforts to understand and treat complex psychiatric disorders.
With support from The Marcus Foundation, an MIT neuroscientist and a Harvard Medical School immunologist will study the “fever effect” in an effort to devise therapies that mimic its beneficial effects.
With full genetic control and visibility into neural activity and behavior, MIT scientists map out chemical’s role in behavior.
While the brain acquires resistance to continuous treatment with mGluR5 inhibitor drugs, lasting effects may still arise if dosing occurs intermittently and during a developmental-critical period.
Novel method, developed by McGovern Institute researchers, may lead to safer, more efficient gene therapies.
Combat veteran and PhD candidate Omar Rutledge drives research on post-traumatic stress disorder.
Gifts to MIT and Harvard Medical School totaling $9 million will fund independent research on cannabinoid’s influence on brain health and behavior.
Finding could improve development of personalized psychiatric treatments.
MIT affiliates recognized for their innovative approaches to energy storage and drug discovery.
Neuroscientists unravel Shank3 gene’s role in autism and schizophrenia.
In talks at MIT, noted behavioral expert suggests encouraging skills of people with autism.
Discovery could lead to new treatments for cognitive disorders including autism and schizophrenia.
Researchers suggest autism stems from a reduced ability to make predictions, leading to anxiety.
Transformative partnership with Ted Stanley will spur researchers to reveal biology of psychiatric disorders.